Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Phase III efficacy and safety data reported for vibegron in overactive bladder

March 27, 2018

Lokelma receives E.U. approval for hyperkalemia

March 23, 2018

Boston Scientific to acquire NxThera

March 22, 2018

Eli Lilly discovers novel PDE1 inhibitors

March 22, 2018

Mereo announces topline phase IIb results for BGS-649 to treat hypogonadotropic hypogonadism

March 19, 2018

OxThera initiates phase III study of Oxabact in primary hyperoxaluria

March 15, 2018

Solifenacin oral suspension for pediatric patients approved in Europe

March 12, 2018

Phase II data presented from the STOP-AKI trial of recAP in sepsis-associated acute kidney injury

March 12, 2018

Allena initiates phase III trial of ALLN-177 in patients with enteric hyperoxaluria

March 7, 2018

Sanifit completes phase II trial of SNF-472 for calciphylaxis in patients on dialysis

March 6, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.